Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO CornerGlobeNewsWire · Oct 15, 2026
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and PartneringGlobeNewsWire · Oct 13, 2026
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in CancersGlobeNewsWire · Oct 1, 2026
Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest UpdateDefense World · Sep 28, 2026
Akari Therapeutics (NASDAQ:AKTX) Stock Crosses Above Fifty Day Moving Average – Should You Sell?Defense World · Sep 9, 2026
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare ForumsGlobeNewsWire · Sep 8, 2026Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$1.04 | -$272.00 | Miss |
| May 19, 2026 | -$1.33 | -$9.74 | Miss |
| Mar 30, 2026 | -$1.80 | -$2.99 | Miss |
| Nov 13, 2025 | -$1.60 | -$4.00 | Miss |
| Aug 13, 2025 | -$3.60 | -$2.40 | Beat |
| May 15, 2025 | – | -$5.40 |